SCHEMBL21322181

SCHEMBL21322181

CC[C@@H](NCC(C)C)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.46
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
KMT2A Q03164 1/20 0.39
FOLH1 Q04609 4/20 0.38
NAALAD2 Q9Y3Q0 2/20 0.38
ACE P12821 1/20 0.35
PLA2G2A P14555 2/20 0.35
PLA2G5 P39877 2/20 0.35
MME P08473 1/20 0.35
KDM4E B2RXH2 1/20 0.34
THRB P10828 1/20 0.34
ALOX15 P16050 1/20 0.34
NFKB1 P19838 1/20 0.34
PTGS2 P35354 1/20 0.34
THPO P40225 1/20 0.34
RECQL P46063 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL564048 1.00 MAPT (0.46) MAPTCYP2D6CYP2C19ALDH1A1MEN1
SCHEMBL14930540 0.83 CHRM1 (0.43) MAPTCYP2D6CYP2C19ALDH1A1MEN1
SCHEMBL25769638 0.82 CYP2D6 (0.39) MAPTCYP2D6CYP2C19ALDH1A1
SCHEMBL21451281 0.82 MME (0.46) MAPTCYP2D6CYP2C19ALDH1A1MEN1
SCHEMBL21451346 0.82 MME (0.46) MAPTCYP2D6CYP2C19ALDH1A1MEN1
SCHEMBL23052781 0.82 MME (0.46) MAPTCYP2D6CYP2C19ALDH1A1MEN1
SCHEMBL2121537 0.82 MAPT (0.60) MAPTCYP2D6CYP2C19ALDH1A1MEN1
SCHEMBL73762 0.82 MAPT (0.60) MAPTCYP2D6CYP2C19ALDH1A1MEN1
SCHEMBL23193782 0.80 FOLH1 (0.36) MAPTALDH1A1MEN1LMNAKMT2A
SCHEMBL22291071 0.80 MAPT (0.44) MAPTCYP2D6CYP2C19ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212155-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. 2023-07-06 US disclosed
EP-4026835-A2 PD-1/PD-L1 INHIBITORS Gilead Sciences, Inc. (US) 2022-07-13 EP disclosed
US-20210323922-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. (US) 2021-10-21 US disclosed
US-20210053946-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. (US) 2021-02-25 US disclosed
US-10710986-B2 PD-1/PD-L1 inhibitors GILEAD SCIENCES, INC. (US) 2020-07-14 US disclosed
US-20190270727-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. 2019-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323922-A1 PD-1/PD-L1 INHIBITORS CD274, PDCD1, PDCD1LG2 MAPT 3105/4885CYP2D6 1713/4885CYP2C19 3024/4885
US-20230212155-A1 PD-1/PD-L1 INHIBITORS PDCD1, CD274, PDCD1LG2 MAPT 3524/4885CYP2D6 1710/4885CYP2C19 3244/4885
US-20210053946-A1 PD-1/PD-L1 INHIBITORS PDCD1, CD274, PDCD1LG2 MAPT 3524/4885CYP2D6 1710/4885CYP2C19 3244/4885
US-10710986-B2 PD-1/PD-L1 inhibitors PDCD1, CD274, PDCD1LG2 MAPT 3524/4885CYP2D6 1710/4885CYP2C19 3244/4885
US-20190270727-A1 PD-1/PD-L1 INHIBITORS PDCD1, CD274, PDCD1LG2 MAPT 3524/4885CYP2D6 1710/4885CYP2C19 3244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.